Cubeddu L X
Department of Pharmacology, School of Pharmacy, Central University of Venezuela, Caracas.
Oncology. 1996 Jun;53 Suppl 1:18-25. doi: 10.1159/000227636.
Emesis is a common side effect of chemotherapeutic drugs. Cisplatin, nitrogen mustard and dacarbazine induce increases in urinary 5-hydroxyindoleacetic acid (5-HIAA) in parallel with the development of the period of emesis which is sensitive to 5-HT3 receptor antagonists ('acute emesis'). It is suggested that these cytotoxics release serotonin from enterochromaffin cells, which then acts on 5-HT3 receptors to trigger the emetic response. Cyclophosphamide, on the other hand, induces a modest emetic response, partly sensitive to 5-HT3 receptor antagonists, but not associated with increases in urinary 5-HIAA. It is suggested that cyclophosphamide-induced emesis is not mediated by the release of serotonin from enterochromaffin cells. Although after high-dose cisplatin most emesis is sensitive to 5-HT3 receptor antagonists, patients often present a milder, although more prolonged form of emesis which is mostly resistant to 5-HT3 receptor antagonists (also known as 'delayed emesis'). This form of emesis is not associated with increases in urinary 5-HIAA (not due to serotonin released from the enterochromaffin cells). Treatment with p-chlorophenylalanine (a serotonin synthesis inhibitor) inhibited cisplatin-induced emesis and cisplatin-induced increases in urinary 5-HIAA excretion. In summary, these results indicate that in human patients, serotonin plays a fundamental role in chemotherapy-induced emesis. Serotonin released from enterochromaffin cells seems to mediate emesis sensitive to 5-HT3 receptor antagonists induced by cisplatin, dacarbazine and nitrogen mustard. Emesis sensitive to 5-HT3 receptor antagonists associated with cyclophosphamide treatment, is not mediated by the release of serotonin from enterochromaffin cells by the cytotoxic. Therefore, cyclophosphamide could induce serotonin release either from enteric serotonin nerves or from the CNS. Cisplatin-induced emesis resistant to 5-HT3 receptor antagonists ('delayed emesis') is not mediated by serotonin released from enterochromaffin cells.
呕吐是化疗药物常见的副作用。顺铂、氮芥和达卡巴嗪会使尿中5-羟吲哚乙酸(5-HIAA)升高,同时出现对5-HT3受体拮抗剂敏感的呕吐期(“急性呕吐”)。提示这些细胞毒性药物促使肠嗜铬细胞释放5-羟色胺,后者作用于5-HT3受体引发呕吐反应。另一方面,环磷酰胺引起适度的呕吐反应,部分对5-HT3受体拮抗剂敏感,但与尿中5-HIAA升高无关。提示环磷酰胺所致呕吐不是由肠嗜铬细胞释放5-羟色胺介导的。虽然大剂量顺铂治疗后多数呕吐对5-HT3受体拮抗剂敏感,但患者常出现一种较轻但持续时间较长的呕吐形式,这种呕吐大多对5-HT3受体拮抗剂耐药(也称为“延迟性呕吐”)。这种呕吐形式与尿中5-HIAA升高无关(并非由肠嗜铬细胞释放的5-羟色胺所致)。用对氯苯丙氨酸(一种5-羟色胺合成抑制剂)治疗可抑制顺铂所致呕吐和顺铂引起的尿中5-HIAA排泄增加。总之,这些结果表明,在人类患者中,5-羟色胺在化疗所致呕吐中起重要作用。肠嗜铬细胞释放的5-羟色胺似乎介导了顺铂、达卡巴嗪和氮芥所致对5-HT3受体拮抗剂敏感的呕吐。环磷酰胺治疗相关的对5-HT3受体拮抗剂敏感的呕吐不是由细胞毒性药物使肠嗜铬细胞释放5-羟色胺介导的。因此,环磷酰胺可能从肠5-羟色胺能神经或中枢神经系统诱导5-羟色胺释放。顺铂所致对5-HT3受体拮抗剂耐药的呕吐(“延迟性呕吐”)不是由肠嗜铬细胞释放的5-羟色胺介导的。